Background & Aims The increasing rates of obesity and type 2 diabetes mellitus may lead to
increased prevalence of nonalcoholic fatty liver disease (NAFLD). We aimed to determine …

Abstract The Malaysian Society of Gastroenterology and Hepatology saw the need for a
consensus statement on metabolic dysfunction‐associated fatty liver disease (MAFLD). The …

Background Nonalcoholic fatty liver disease (NAFLD) is a common metabolic disease that
affects 20–30% of individuals worldwide. Liver puncture remains the gold standard for the …

Abstract Background and Aim Multiple clinical trials have been conducted to study the
potential benefits of vitamin E for the treatment of metabolic dysfunction‐associated steatotic …

Background In this study, the network pharmacological methods were used to predict the
target of active components of Chaihu Lizhong Tang (CHLZT) in the treatment of non …

Background There are limited data on the long-term adverse clinical outcomes of adults with
metabolic dysfunction-associated fatty liver disease (MAFLD). Methods This is a single …

Introduction Metabolic syndrome (MetS) is a cluster of cardio-metabolic dysfunctions
characterised by increased fasting plasma glucose, waist circumference, blood pressure …

Background Non-alcoholic fatty liver disease (NAFLD) and metabolic-associated fatty liver
disease (MAFLD) shares common pathophysiological mechanisms with type 2 diabetes …

Metformin was developed from an offshoot of Guanidine. It is known to be the first-line
medication for type 2 diabetes mellitus, polycystic ovarian syndrome, and weight reduction …

Background Viral hepatitis B and C (HBV, HCV) and non-alcoholic fatty liver disease
(NAFLD) are the commonest etiologies of liver-related deaths in Malaysia. Herein, this study …